Wealthfront Advisers’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.36M Sell
81,269
-4,994
-6% -$403K 0.01% 396
2026
Q1
$7.47M Sell
86,263
-4,552
-5% -$436K 0.02% 330
2025
Q4
$8.72M Buy
90,815
+4,272
+5% +$415K 0.02% 278
2025
Q3
$8.24M Buy
86,543
+11,104
+15% +$1.02M 0.02% 278
2025
Q2
$6.58M Sell
75,439
-10,566
-12% -$896K 0.02% 317
2025
Q1
$7.73M Buy
86,005
+24,000
+39% +$2.15M 0.02% 250
2024
Q4
$4.95M Buy
62,005
+30
+0% +$2.6K 0.01% 333
2024
Q3
$5.58M Buy
61,975
+196
+0.3% +$16.5K 0.02% 277
2024
Q2
$4.86M Sell
61,779
-10,576
-15% -$867K 0.02% 276
2024
Q1
$6.31M Buy
72,355
+9,677
+15% +$826K 0.02% 221
2023
Q4
$5.16M Sell
62,678
-26,556
-30% -$2.02M 0.02% 236
2023
Q3
$6.99M Sell
89,234
-14,394
-14% -$1.2M 0.03% 161
2023
Q2
$9.13M Buy
103,628
+17,392
+20% +$1.5M 0.04% 133
2023
Q1
$6.95M Buy
86,236
+53,522
+164% +$4.36M 0.03% 160
2022
Q4
$2.54M Sell
32,714
-38,055
-54% -$3.08M 0.01% 344
2022
Q3
$5.71M Buy
70,769
+4,045
+6% +$364K 0.03% 155
2022
Q2
$5.99M Sell
66,724
-29,756
-31% -$3.01M 0.03% 160
2022
Q1
$10.7M Buy
96,480
+34,461
+56% +$3.64M 0.05% 92
2021
Q4
$6.42M Sell
62,019
-35,940
-37% -$4.16M 0.03% 156
2021
Q3
$12.3M Buy
97,959
+17,429
+22% +$2.26M 0.06% 67
2021
Q2
$10M Buy
80,530
+2,288
+3% +$287K 0.05% 71
2021
Q1
$9.24M Buy
78,242
+1,701
+2% +$199K 0.05% 70
2020
Q4
$8.97M Buy
76,541
+3,267
+4% +$360K 0.05% 62
2020
Q3
$7.62M Buy
73,274
+16,566
+29% +$1.66M 0.05% 70
2020
Q2
$5.2M Sell
56,708
-7,616
-12% -$730K 0.04% 79
2020
Q1
$5.8M Buy
64,324
+29,320
+84% +$3.12M 0.05% 64
2019
Q4
$3.97M Buy
35,004
+1,074
+3% +$118K 0.03% 99
2019
Q3
$3.69M Buy
33,930
+4,564
+16% +$476K 0.03% 94
2019
Q2
$2.86M Sell
29,366
-3,800
-11% -$347K 0.02% 113
2019
Q1
$3.02M Sell
33,166
-11,278
-25% -$1.01M 0.03% 100
2018
Q4
$4.04M Buy
+44,444
New +$4.15M 0.04% 75

Other funds holding MDT

Wealthfront Advisers's MDT Position: Q2 2026 in Review

Wealthfront Advisers reduced its Medtronic (MDT) stake by 5.8% in Q2 2026, selling an estimated $403K and leaving 81,269 shares worth $6.36M. The position accounts for 0.01% of the portfolio, ranked #396.

Wealthfront Advisers first reported a position in MDT in Q4 2018 and has held it in 31 quarters since. The position peaked at $12.3M in Q3 2021. 2,132 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Wealthfront Advisers held 81,269 shares of Medtronic worth $6.36M as of Q2 2026.
  • Wealthfront Advisers sold 4,994 Medtronic shares in Q2 2026, an estimated $403K.
  • Medtronic made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #396 holding.
  • Wealthfront Advisers first reported a position in Medtronic in Q4 2018 and has held it in 31 quarters since.
  • Wealthfront Advisers's Medtronic position peaked at $12.3M in Q3 2021.
  • 2,132 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.